| Literature DB >> 24793731 |
Andrew M Brunner1, Traci M Blonquist2, Hossein Sadrzadeh3, Ashley M Perry3, Eyal C Attar3, Philip C Amrein3, Karen K Ballen3, Yi-Bin Chen3, Donna S Neuberg2, Amir T Fathi4.
Abstract
We performed a retrospective population-based study using the SEER database to assess survival trends in CBF-AML between 2000 and 2010. Median OS increased from 16 months in 2000-2002 to 25 months in 2006-2008 (P=0.002). The 3-year OS rate for patients with inv(16) was 57.3%, but in t(8;21) was only 35.5%. Patients aged 75-84 had worse survival than patients aged 15-44 (HR 5.61, P=0.0002). Black race was associated with higher mortality (HR 1.50, P=0.03). Compared to clinical trial outcomes, CBF-AML survival is poorer in the general population, particularly among African Americans and the elderly, and in t(8;21) compared to inv(16) AML.Entities:
Keywords: Acute myeloid leukemia; Core binding factors; Health status disparities; Population surveillance; Survival
Mesh：
Substances：
Year: 2014 PMID： 24793731 PMCID： PMC4214756 DOI： 10.1016/j.leukres.2014.04.001
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156